目的：评估关节腔内注射贝伐单抗治疗兔膝骨性关节炎的效果。方法： 24只新西兰兔制造原发性骨关节炎模型后随机分入贝伐单抗组、透明质酸钠(sodium hyaluronate, SH)组和对照组，每组8只。贝伐单抗组和对照组关节腔各自注射4.0 mg贝伐单抗和生理盐水，每3周1次，连续实验6周，各组分别注射2次；SH组进行SH关节腔内注射，每周1次，连续实验6周，共6次。6周后观察各组软骨和滑膜组织病理切片，滑膜电子显微镜及血管免疫组织化学SP法染色，软骨大体观察评分，MMP-1的免疫组织化学表达，以及Mankin’s评分。结果：病理切片显示贝伐单抗组较SH组和对照组血管生成明显减少，抑制滑膜增生，改善了软骨结构及基质成分；滑膜血管内皮生长因子(vascular endothelial growth factor,VEGF)阳性细胞百分数、平均光密度值、软骨MMP-1细胞百分数、Mankin’s评分及软骨大体评分均显示贝伐单抗组小于SH组和对照组（P<0.05），SH组小于对照组（P<0.05）。结论：贝伐单抗能减少血管生成，抑制滑膜增殖，减少MMP-1的生成，对软骨有保护作用，并且优于SH，对兔膝原发性骨性关节炎有治疗作用，这为临床膝原发性骨性关节炎关节腔内药物治疗提供了一种可能的方案。

Objective：To evaluate the effects of intraarticular injection of bevacizumab、sodium hyalu-ronate (SH) and 0.9% sodium chloride injection in the treatment of osteoarthritis (OA) in a rabbit model. Methods: Twenty-four male rabbits were randomly divided into bevacizumab group,SH group and control group after the model of OA had been made. The bevacizumab group and control group received intraarticular bevacizumab (4 mg) and 0.9% saline injection respectively once per three weeks for 2 times. The SH group received intraarticular SH once a week for 6 weeks. After 6 weeks, the histological examinations of cartilage and synovium,electron microscopy and expression of vasculan endothelial growth factorl (VEGF）, for the synovium, expression of MMP-1, Mankin’s scale, macroscopic observation for cartilage were performed. Results: The histological observation of the bevacizumab group and the SH group showed that bevacizumab could decrease the synoviocytes and inhibit fibrous hyperplasia in synovial underlayer compard with the control group. Reduced apoptosis of chondrocytes and more integrated structure of matrix and more glycosaminoglycan were also found in the bevacizumab group and the SH group compared with control group. The expression of VEGF and MMP-1, Mankin’s scale, macroscopic observation were significantly decreased in the bevacizumab group compared with the SH group and the control group (P<0.05). Conclusion: Intraarticular injection of bevacizumab and SH can relieve inflammation of OA and alleviate the pathologic process of OA. The Bevacizumab was better than the SH in therapeutic effect, which maybe implicate a better choice for the treatment of OA.